Drug Trial Radar · NCT05406999
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Feb 1, 2020
Primary completion
Dec 31, 2026
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
Conditions
- Neoadjuvant Therapy
- High Risk Prostate Cancer
- Locally Advanced Prostate Cancer
- Intense Endocrine Therapy
Interventions
ADTDrug
The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
Abiraterone AcetateDrug
1000 mg (250 mg×4 tablets) once daily, orally
Prednisolone tabletsDrug
5 mg once daily, orally.
EnzalutamideDrug
160 mg (40 mg× 4 tablets) once daily, orally.
ApalutamideDrug
240 mg (60 mg×4 tablets) once daily, orally.
DarotamideDrug
600 mg (300 mg × 2 tablets) twice daily, orally.
RezvilutamideDrug
240 mg (80 mg × 3 tablets) once daily orally
PARP inhibitorDrug
The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
Robot-assisted radical prostatectomyProcedure
Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic response rateTime frame: up to 3 years
- 3 year biochemical progression free survival (bPFS)Time frame: up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.